Overview

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

Status:
RECRUITING
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Phase:
PHASE3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Tirzepatide